Day: December 17, 2025

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement with a new large global pharmaceutical customer. Under the terms of the agreement, Lifecore will conduct development services and tech transfer for an injectable pharmaceutical product with the intent to transfer commercial supply from facilities overseas to Lifecore’s facilities. Once commercial transfer activities are complete and all regulatory requirements...

Vancouver, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that is has staked an additional 90 claims, approximately 6 square kilometers or 1500 acres, with strong antimony-gold prospectivity at its Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada. The newly staked ground has the same geological signatures as other antimony-gold targets at the Project. Aerial Drone Footage of 2025 Drilling & High-Grade Antimony Bullet Zone Discovery (Click Here): Key HighlightsAdded an additional 90 claims, approximately 6 square kilometers or 1500 acres, with strong antimony-gold prospectivityThe new claims encompass remaining surface exposure of a dolomite-over-Pilot Shale thrust block, as well as exposed...

MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has issued a notice of partial redemption for US$500 million aggregate principal amount of its outstanding 6.000% Senior Notes due 2028 (the “2028 Notes”). As set forth in the notice of partial redemption issued today in respect of the 2028 Notes, the redemption date is February 15, 2026, and the redemption price for the 2028 Notes is 100% of the principal amount redeemed, plus accrued and unpaid interest. This debt redemption will be funded using cash from Bombardier’s balance sheet. On December 17, 2025, a copy of the notice of partial redemption with respect to the 2028 Notes was issued to the record holders thereof. Payment of the redemption price and surrender of the 2028 Notes for redemption will be made through the facilities...

Evolve commence trading on the CSE today, December 17, 2025 under the ticker symbol “EVR” Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — Evolve Royalties Ltd. (CSE: EVR) (“Evolve” or the “Company”) is pleased to announce that its common shares have commenced trading on the Canadian Securities Exchange (the “CSE”) under the symbol “EVR.” “Today marks an important milestone for Evolve as we begin trading on the CSE,” said Joseph de la Plante, President & CEO of Evolve. “Over the past year, we have assembled a copper-focused royalty portfolio anchored by Highland Valley Copper and Copper Mountain—two of Canada’s largest copper operations—and most...

The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose cancers initially responded to treatment with osimertinib but subsequently acquired resistance to treatment Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib...

TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced it has exercised its right to call all 500,000 outstanding common share purchase warrants (the “Warrants”) issued in connection with its October 20, 2025 non-brokered private placement financing. The Warrants issued in connection with Abaxx’s October 2025 private placement contained a provision allowing Abaxx to exercise a redemption right to call the Warrants in the event the daily VWAP of Abaxx’s common shares traded on Cboe Canada...

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed...

FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, titled “Early Genetic Evolution of Driver Mutations in Uveal Melanoma,” was conducted by the Collaborative Ocular Oncology Group (COOG) and recently published in Nature Communications. “The recently published COOG2 study validated that combining DecisionDx-UM test results and PRAME gene expression data provides more precise...

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST. The live webcast will be available under the “Events & Presentations” tab on the “Investors” page of the Company’s website on the day of the event. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer....

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT/10:30 a.m. ET. A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepoint.bio. About EyePoint EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s...